Zhongxia Zhou

发表

Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2021, Bioorganic & medicinal chemistry.

Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors

E. De Clercq, Dongwei Kang, Boshi Huang, 2019, Communications Chemistry.

Discovery of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2017, ACS medicinal chemistry letters.

Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014–2017)

Peng Zhan, Dongwei Kang, Gaochan Wu, 2018, Expert opinion on therapeutic patents.

Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2018, ACS medicinal chemistry letters.

Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.

Dongwei Kang, Boshi Huang, C. Pannecouque, 2018, ACS medicinal chemistry letters.

Influenza A virus polymerase: an attractive target for next-generation anti-influenza therapeutics.

P. Zhan, Xinyong Liu, Jian Zhang, 2018, Drug discovery today.

Arylazolyl(azinyl)thioacetanilides: Part 19 : Discovery of Novel Substituted Imidazo[4,5‐b]pyridin‐2‐ylthioacetanilides as Potent HIV NNRTIs Via a Structure‐based Bioisosterism Approach

E. De Clercq, Boshi Huang, C. Pannecouque, 2016, Chemical biology & drug design.

Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.

E. De Clercq, Boshi Huang, Huiqing Liu, 2017, European journal of medicinal chemistry.

Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.

E. De Clercq, Dongwei Kang, Boshi Huang, 2016, Bioorganic & medicinal chemistry.

Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored "hydrophobic channel".

E. De Clercq, Dongwei Kang, C. Pannecouque, 2018, Organic & biomolecular chemistry.

Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.

Peng Zhan, Jan Balzarini, Christophe Pannecouque, 2014, Bioorganic & medicinal chemistry.

Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors.

Dongwei Kang, P. Zhan, Xinyong Liu, 2019, Drug discovery today.

Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2019, Organic & biomolecular chemistry.

First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.

E. De Clercq, Dongwei Kang, Boshi Huang, 2018, Bioorganic & medicinal chemistry letters.

Molecular design opportunities presented by solvent‐exposed regions of target proteins

Peng Zhan, Erik De Clercq, Yuning Song, 2019, Medicinal research reviews.

Design, synthesis, and antiviral evaluation of novel hydrazone‐substituted thiophene[3,2‐d]pyrimidine derivatives as potent human immunodeficiency virus‐1 inhibitors

E. De Clercq, Dongwei Kang, C. Pannecouque, 2018, Chemical biology & drug design.

The development of an effective synthetic route of rilpivirine

Dongwei Kang, P. Zhan, Xinyong Liu, 2021, BMC Chemistry.

1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries.

Lingzi Zhang, C. Pannecouque, P. Zhan, 2017, Bioorganic & medicinal chemistry.

First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via ‘privileged scaffold’ refining approach

Peng Zhan, Lieve Naesens, Heng Zhang, 2016, Bioorganic & Medicinal Chemistry Letters.

Design, synthesis, and antiviral evaluation of novel piperidine-substituted arylpyrimidines as HIV-1 NNRTIs by exploring the hydrophobic channel of NNIBP.

E. De Clercq, Dongwei Kang, C. Pannecouque, 2021, Bioorganic chemistry.

Discovery of potent HIV‐1 non‐nucleoside reverse transcriptase inhibitors by exploring the structure–activity relationship of solvent‐exposed regions I

E. De Clercq, Dongwei Kang, C. Pannecouque, 2019, Chemical biology & drug design.

Identification of Novel Diarylpyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors by Exploring the Primer Grip Region

E. De Clercq, Dongwei Kang, C. Pannecouque, 2022, Pharmaceuticals.

Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.

Peng Zhan, Xiao Ding, Dongwei Kang, 2016, Journal of medicinal chemistry.

Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.

Peng Zhan, Xiao Ding, Ye Tian, 2017, Journal of medicinal chemistry.

Identification of Boronate-Containing Diarylpyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

Dongwei Kang, C. Pannecouque, P. Zhan, 2022, Molecules.

Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.

Peng Zhan, Ye Tian, Dongwei Kang, 2017, European journal of medicinal chemistry.

Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2)

Dongwei Kang, Boshi Huang, P. Zhan, 2017, Expert opinion on therapeutic patents.